Table 1.

Basic clinical features of 15 literature were included in our study.

Study	Age	Gender	Follow-up time (month)	The experimental group (N)	Control group (N)	NOS score	HAMD score
Liu 2017	53.71 ± 2.2	Female	3 ~ 12	52/66	15/31	8	26.12 ± 4.75
Chen 2018	55.65 ± 3.4	Female	12~24	178/262	112/386	7	23.22 ± 2.75
Simmons 2016	63.12 ± 4.5	Female	6 ~ 12	118/142	98/217	8	25.15 ± 4.02
Xiang 2017	57.15 ± 4.5	Female	6 ~24	78/133	21/43	7	23.45 ± 4.15
Rosen 2005	42.85 ± 8.4	Female	6 ~24	156/296	140/296	8	21.12 ± 4.05
Zhu 2021	64.36 ± 1.2	Female	4 ~ 12	93/179	86/179	7	28.12 ± 3.75
Cho 2019	62.62 ± 2.2	Female	6 ~ 12	50/81	31/81	9	28.21 ± 1.75
Yu 2020	62.61 ± 3.0	Female	6 ~ 18	67/102	35/102	9	27.12 ± 3.22
Xu 2021	57.25 ± 4.5	Female	6 ~24	45/75	30/75	7	29.46 ± 2.55
Freydanck 2012	56.22 ± 5.2	Female	4 ~24	32/56	24/56	8	26.42 ± 5.05
Chen 2015	61.35 ± 8.1	Female	3 ~ 12	178/323	145/323	7	24.13 ± 4.11
Chen 2017	47.25 ± 6.0	Female	4 ~ 14	98/178	80/178	7	26.16 ± 2.75
Gao 2021	58.51 ± 2.6	Female	6 ~24	40/65	25/65	9	26.18 ± 3.72
Huang 2015	66.34 ± 22.5	Female	6 ~24	48/78	30/78	8	28.16 ± 4.86
Tang 2021	62.51 ± 4.6	Female	4 ~ 12	112/190	78/190	9	25.16 ± 1.86